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Genetic connections between neurological disorders and
cholesterol metabolism
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THE ROLE OF CHOLESTEROL AND ITS TURNOVER
IN THE NERVOUS SYSTEM
The mammalian nervous system contains a disproportionate amount of cholesterol. In the brain, the cholesterol content is about 10-fold greater than in any other
organ (1). The development of the capacity to synthesize
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Blanceflor Foundation nee’ Bildt.
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Published, JLR Papers in Press, May 13, 2010
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and store such a large amount of cholesterol indicates that
there is a close link between the evolution of the nervous
system and a specific role for cholesterol. Within the brain,
some 70% of cholesterol is present in myelin, where it fulfills
a critical insulating role. It is likely that the requirement
for efficient signaling despite a small transverse diameter
of axons was a key selective pressure driving the accretion
of cholesterol in the mammalian brain (1, 2). The requirement for large amounts of cholesterol is further underscored by the long half-life of brain cholesterol; overall
brain cholesterol turns over some 250–300 times slower than
that in the circulation (3).
At a cellular level, the myelin sheath consists of sections
of plasma membrane repeatedly wrapped around an axon,
with the extrusion of virtually all of the cytoplasm. Myelin
is formed by 2 very specialized cells: the oligodendrocyte
in the central nervous system (CNS) and the Schwann cell
in the peripheral nervous system (PNS). Because an individual axon may be ensheathed by myelin from several oligodendrocytes, periodic gaps are present in the sheath.
These are called the “nodes of Ranvier” and are the site of
propagation of the action potential. Myelin can thus be
regarded as a discontinuous insulation that enables the saltatory conduction of the action potential (1, 2). In addition
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Abstract Cholesterol is an essential component of both the
peripheral and central nervous systems of mammals. Over
the last decade, evidence has accumulated that disturbances
in cholesterol metabolism are associated with the development of various neurological conditions. In addition to genetically defined defects in cholesterol synthesis, which will
be covered in another review in this Thematic Series, defects
in cholesterol metabolism (cerebrotendinous xanthomatosis)
and intracellular transport (Niemann Pick Syndrome) lead to
neurological disease. A subform of hereditary spastic paresis
(type SPG5) and Huntington’s disease are neurological
diseases with mutations in genes that are of importance for
cholesterol metabolism. Neurodegeneration is generally associated with disturbances in cholesterol metabolism, and
presence of the E4 isoform of the cholesterol transporter
apolipoprotein E as well as hypercholesterolemia are important risk factors for development of Alzheimer’s disease.
In the present review, we discuss the links between genetic
disturbances in cholesterol metabolism and the above neurological disorders.—Björkhem, I., V. Leoni, and S. Meaney.
Genetic connections between neurological disorders and
cholesterol metabolism. J. Lipid Res. 51: 2489–2503.
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which is able to pass across the blood-brain barrier and
enter the circulation (3, 8, 9). In addition, there is a small
efflux of cholesterol from the brain in the form of apolipoprotein (APO) E containing lipoproteins via the cerebrospinal fluid (10). The mechanism by which cholesterol is
eliminated from the PNS is not known with certainty, and
the spinal cord does not appear to be able to synthesize
24S-OHC.
The stability of the bulk of cholesterol in the CNS and in
the spinal cord is in marked contrast to the rapidly changing levels of plasma lipoproteins under different conditions.
The turnover of the cholesterol present in membranes of
the neuronal cells and in astrocytes may, however, change
in response to different factors. Under normal conditions,
cholesterol 24-hydroxylase (CYP46A1), the enzyme system
responsible for formation of 24S-OHC, is present only in
neuronal cells, with particularly high levels in the pyramidal
neurons in various layers of the cortex, in the hippocampus, and in Purkinje cells in the cerebellum (9). The uptake of cholesterol by these cells may thus be balanced by
the secretion of 24S-OHC. The 24S-OHC secreted from
the neuronal cells may be of importance for regulation of
cholesterol synthesis and secretion of this cholesterol in
APOE-bound form from astroglia. The latter effects may
be mediated by the liver X receptor (LXR) (5, 11).
In the liver, the conversion of cholesterol into bile acids
is regulated by highly sophisticated mechanisms (12). In
the brain, however, the expression of CYP46A1 appears to
be resistant to regulatory axes, which are known to regulate cholesterol homeostasis and bile acid synthesis (13).
Indeed, the putative promoter region of CYP46A1 has the
characteristics of a housekeeping gene (13), although recent data indicate that epigenetic mechanisms may regulate CYP46A1 expression (14, 15). In contrast, cholesterol
synthesis appears to be regulated by similar mechanisms
both outside and inside the brain, with hydroxy-methylglutaryl CoA reductase (HMGCR) being the most important regulatory enzyme (2). However, in the brain, cholesterol
synthesis via the 7-dehydrodesmosterol pathway seems to
be preferred over the 7-dehydrocholesterol pathway, and
disruption of the gene coding for the ⌬24-reductase results in the accumulation of desmosterol without any accumulation of 7-dehydrodesmosterol (16).
In the Cyp46a1 null mouse, loss of the main pathway for
cholesterol elimination results in a compensatory 40% decrease in cholesterol synthesis, while the overall content of
brain cholesterol is normal. There are, however, significant
behavioral changes and reduced memory function, indicating that a certain rate of flux through the mevalonate
pathway is necessary to support memory consolidation
(17). In subsequent studies, the isoprenoid geranylgeraniol was identified as the important intermediate, and it
was suggested the Cyp46a1-mediated removal of cholesterol from neurons is critical to prevent cholesterol accumulation, feedback inhibition of cholesterol synthesis, and a
decreased production of essential isoprenoid intermediates
[reviewed in (9)].
Although formation of 24S-OHC is responsible for the
removal of about two-thirds of cholesterol from the brain,
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to a large lipid component, myelin also contains many specific proteins such as proteolipid protein and myelin basic
protein. Recently, evidence has been presented that cholesterol can regulate the correct targeting of one of the
major membrane proteins of the PNS and thereby myelin
compaction. These data extend the role of cholesterol in
myelin from an essential structural component to a regulator of overall myelin structure (4).
The remaining 30% of brain cholesterol is divided between glial cells (20%) and neurons (10%). According to
various in vitro studies with cultured cells, astrocytes synthesize at least 2- to 3-fold more cholesterol than neurons,
and oligodendrocytes have an even higher capacity for cholesterol synthesis, at least during periods of active myelination [for a more detailed review, see ref (3)]. It has also been
suggested that in the mature state, the neurons synthesize
only a relatively small amount of cholesterol, and instead
they rely almost totally on the supply of cholesterol from
glial cells, especially astrocytes in the CNS (5). Studies using
conditional ablation of a key gene in cholesterol synthesis
have provided evidence that at least some adult neurons can
survive without any de novo cholesterol synthesis (6, 7).
It is noteworthy that even minor changes in the structure of the constituent sterols of the nervous system, e.g., the
presence of one additional double bond, leads to a change
in the biophysical properties of the cell membrane with
profound clinical effects. This is illustrated by the severity
of the neurological phenotypes associated with defects
in cholesterol synthesis, which lead to the incorporation of
a cholesterol precursor such as desmosterol or 7-dehydrocholesterol into cell membranes. For a detailed review, see
the review from Porter in this Thematic Series.
In the cells outside the CNS, the overall cholesterol
homeostasis is achieved by de novo synthesis, uptake of
lipoprotein-bound cholesterol, and efflux of cholesterol.
In addition to this, liver can eliminate cholesterol by conversion into polar bile acids. When challenged with high
levels of exogenous cholesterol, the excess can be stored
in an esterified form.
The strategy used by nature for cholesterol homeostasis
in the brain and spinal cord is different from that in other
parts of the body. Due to the efficient blood-brain barrier,
there is no passage of lipoprotein-bound cholesterol from
the circulation to the brain (1, 3). The blood-brain barrier
thus prevents diffusion of large molecules at the level of
tight junctional attachments between adjacent capillary
endothelial cells. In addition to this, there is also no transvesicular movement of solution across the capillaries. It is
possible that one or more members of the ATP binding
cassette transporter superfamily may be involved in the exclusion of circulating cholesterol from the brain, but conclusive evidence is lacking for this.
Thus, all the cholesterol present in the brain is formed
by de novo synthesis, and the same is true also for the cholesterol in the PNS. Except for the active phase of specific
pathological conditions, almost all (at least 99%) cholesterol in the nervous system is unesterified. In the adult brain,
most of its synthesis is balanced by formation of a hydroxylated metabolite, 24S-hydroxycholesterol (24S-OHC),

under normal conditions, APOE seems to be the most important carrier of cholesterol in the brain extracellular
fluid. In view of this, it is surprising that deletion of APOE
does not appear to lead to any major functional abnormalities in the brain, although there is a compensatory
increase in the expression of APOD (18). In aged APOE
knockout mice, however, there is a lipid deposition in astrocytes in hippocampus and thalamus (19). In addition to
APOE and APOD, there are other apolipoproteins in the
brain, such as APOJ (also known as clusterin) and APOA1,
that may be of importance (3).

THE ROLE OF O XYSTEROLS

Fig. 1. Cross-talk of oxysterols across the blood-brain barrier
(3,27).

the balance between 24S-OHC and 27-OHC in the brain is
of importance for neurodegeneration (28, 29). In light of
the importance of an adequate flux of intermediates
through the mevalonate pathway, the entry of an inhibitory compound into the brain may have deleterious downstream consequences for cognition.

DEFECTS IN CHOLESTEROL SYNTHESIS
In view of the importance of cholesterol, it is not surprising that relatively few disorders in the synthesis of this molecule are compatible with life. The disorders are associated
with accumulation of a cholesterol precursor (lathosterol,
desmosterol, or 7-dehydrocholesterol) and severely debilitating and frequently fatal birth defects. For a detailed review, see the review from Porter in this Thematic Series.
Cerebrotendinous xanthomatosis
The patients are characterized by dementia, ataxia, cataracts, and xanthomas in the tendons and in the nervous
system. Typical onsets of the disease consists of early bilateral cataracts and diarrhea, followed by cerebellar and pyramidal signs, mental retardation, and xanthomas.
In contrast to the situation in familial hypercholesterolemia, the xanthomas contain high levels of cholestanol,
the 5␣-saturated analog of cholesterol.
This rare autosomal recessive genetic disorder is caused
by a mutation in CYP27A1 that encodes the cytochrome
P-450 enzyme sterol 27-hydroxylase [for reviews, see (30,
31)]. The gene contains nine exons and spans 18.6 kb of
DNA. The enzyme comprises 498 amino acids and contains putative binding sites for heme ligands and adrenodoxin. CYP27A1 is located at the inner mitochondrial
membranes.
CYP27A1 is important for the normal oxidation of the
steroid side-chain in connection with biosynthesis of bile
acids (12) and is the rate limiting step in the conversion of
the C27-steroid into a C24-steroid. The preferred substrates for the enzyme are thus 7␣-hydroxylated intermediates in bile acid synthesis. The enzyme is, however, also
active on cholesterol. Because the enzyme is likely to be
present and active in most cells in the body, and all cells
Cholesterol and neurological disease
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Side-chain oxidized oxysterols (SCOx) such as 24S-OHC
have the capacity to traverse biological membranes, and
there is a concentration-driven flux of this oxysterol from
the brain into the circulation (20). This flux corresponds
to an elimination of 6–7 mg cholesterol/24 h (3). The oxysterol is taken up by the liver and further oxidized to bile
acids (8). In addition to the role of 24S-OHC in the elimination of cholesterol, it may be of importance in connection with neurodegeneration. Under in vitro conditions,
this oxysterol stimulates ␣-secretase activity and inhibits
␤-secretase activity in neuronal cell lines (21–23). This is
consistent with a preventive effect of 24S-OHC on generation of amyloid. In accordance with this, it was recently
reported that injection of adeno-associated vector encoding CYP46A1 in the cortex and hippocampus of amyloid
precursor protein (APP)-mutated mice before the onset of
amyloid deposits markedly reduced these deposits (24). In
addition, the treatment caused improvement in spatial
memory. Further support for the contention that increased
formation of 24S-OHC is beneficial was presented in a very
recent report demonstrating that disruption of the gene
coding for the esterification enzyme ACAT1 in a mouse
model of Alzheimer’s disease (AD) had a beneficial effect
on amyloid generation and memory function (25). Evidence was given that at least part of this effect was mediated by increased levels of 24S-OHC.
A related SCOx, 27-hydroxycholesterol (27-OHC), has
similar physiochemical properties to 24S-OHC and is also
able to pass the blood-brain barrier. There is only a low
production of this oxysterol in CNS, and most of the 27OHC present in the brain and cerebrospinal fluid originates from extracerebral sources. Although there is a
substantial uptake of 27-OHC by the brain, about 5 mg/24
h (26), the steady-state levels within the brain are very low
due to a rapid metabolism into a steroidal acid (27). This
acid fluxes from the brain into the circulation and is rapidly metabolized in the liver (27). Oxysterol 7␣-hydroxylase
(CYP7B1) seems to be the most critical enzyme in this conversion. Similarly to CYP46A1, this enzyme seems to be exclusively located to the neuronal cells. Figure 1 summarizes
the flux of oxysterols across the blood-brain barrier.
27-OHC is a potent inhibitor of cholesterol synthesis
and has been shown to antagonize the beneficial effects of
24S-OHC to reducing amyloid accumulation in cultured
neuronal cells (22). Based on this, we have suggested that
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fective suppressor of the rate-limiting enzyme cholesterol
7␣-hydroxylase (CYP7A1) in humans (34). Thus, there is a
marked upregulation of CYP7A1 in CTX, and the levels of
7␣-hydroxy-4-cholesten-3-one in the circulation may be increased up to 100-fold (35). The latter steroid is able to
pass the blood-brain barrier and may be converted into
cholestanol in the brain (36). It is noteworthy that treatment with chenodeoxycholic acid reverses the biochemical changes, and even the xanthomas in the brain may be
reduced or disappear as a consequence of such treatment
(37). In some of the latter patients, the treatment with
chenodeoxycholic acid was shown to improve cognition
(36).
The reason for the accumulation of cholesterol in
parallel with cholestanol in the xanthomas is not clear.
Cholestanol is, however, less efficient than cholesterol in
suppressing cholesterol synthesis (38), and a dilution of a
cholesterol pool with cholestanol may cause a compensatory increased synthesis of cholesterol. In some experiments with experimental animals, dietary treatment with
cholestanol has been shown to increase cholesterol synthesis (39, 40).
In addition to formation of cholestanol, the accumulation of 7␣-hydroxylated intermediates in bile acid synthesis leads to formation of 7␣- and 25-hydroxylated alcohols,
e.g., 5␤-cholestane-3␣,7␣,12␣,25-tetrol. These alcohols
may be secreted in bile and urine in gram amounts, and
detection of these compounds is generally used in the diagnosis of the disease.
It is noteworthy that a disruption of the gene coding
for the Cyp27a1 in mice does not lead to formation of
xanthomas in tendons or brain (41). There is some accumulation of cholestanol in these structures, in particular in female mice, but this accumulation is less marked
and is not accompanied by accumulation of cholesterol
(Björkhem, unpublished observation). The reason for the
difference between human CTX and the corresponding
mouse model is not known with certainty. Part of the explanation may be that the degree of upregulation of the
CYP7A1 as a consequence of the lack of the CYP27A1 is
less marked in the mouse model than in patients with
CTX.
Hereditary spastic paresis type SPG5
Hereditary spastic paresis (HSP) is a genetically and
clinically very heterogenous group of upper motor neuron
degenerative diseases (42–46). The disease is characterized by selective axonal loss in the corticospinal tracts and
dorsal columns. The cardinal features consist of progressive spasticity of the lower limbs and muscle weakness, frequently associated with deep sensory loss and urinary
urgency. These features define “pure” HSP, while “complex” or “complicated” HSP are accompanied by other
neurological signs such as ataxia, mental retardation, dementia, visual dysfunction, and epilepsy. The different
subgroups of HSP are associated with all modes of inheritance and about 40 loci have been described. The first
pure autosomal-recessive HSP locus defined was called
SPG5, located on chromosome 8q12.3.
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contain cholesterol, there is some production of 27-OHC
in most cells. Because 27-OHC is able to pass cell membranes, there is a continuous concentration-dependent
flux of 27-OHC to the two organs containing efficient metabolizing systems, i.e., the liver and the brain. In the liver,
27-OHC and its peripheral metabolites are further oxidized into bile acids. The flux of 27-OHC and its metabolites to the liver can be regarded as an alternative
mechanism to the classical HDL-dependent reversed cholesterol transport and may be regarded as antiatherogenic
(20, 32). In accordance with this, the levels of CYP27A1
activity are particularly high in macrophages and endothelial cells (20, 31).
The activity of CYP27A1 is dependent upon NADPH
and the availability of two electron transporters, adrenodoxin and adrenodoxin reductase (12). Additionally, it
seems likely that specific transporters are required to transport cholesterol to CYP27A1 on the inner mitochondrial
membranes. At present, no mutation causing cerebrotendinous xanthomatosis (CTX) has been defined in any
other protein than CYP27A1. There is, however, a description of a CTX patient with a heterozygous mutation in
CYP27A1 who is likely to have a mutation in some additional protein, possibly a protein responsible for transport
of cholesterol into the mitochondria (33). The possibility
of an exon deletion was excluded. This subject has very
low levels of 27-OHC in the circulation. Normally, subjects
with a heterozygote mutation in the CYP27A1 gene have
levels of 27-OHC about one-half those of normal and have
no symptoms.
Currently, more than 300 CTX cases have been described in the literature, with distinctive clusters in Japan,
The Netherlands, and Israel. About 30 different mutations
in the CYP27A1 gene have been described (missense, nonsense, frameshift, and splice junction).
The activity of the enzyme is dependent upon a binding
of the electron carrier adrenodoxin as well as binding of
heme, and the mutations causing CTX are all located in
the adrenodoxin binding or heme ligand binding sites
(31). Diagnosis of CTX is obtained by assay of 27-OHC,
cholestanol, and bile alcohols in the circulation and MRI.
Cholesterol levels are increased in the tissues but not in
the circulation. The most serious consequence of the disease is the development of xanthomas in the brain and the
neurological symptoms caused by this. The preferential
site of the brain xanthomas is in the white matter of the
cerebellum (30).
Generation of cholestanol is likely to be the driving
force in this disease, and accumulation of cholesterol is
likely to be secondary to this. Most of the excess cholestanol
appears to be derived from 7␣-hydroxylated intermediates
during the synthesis of bile acids. Because CYP27A1 is required for oxidation of the steroid side chain in the normal biosynthesis of bile acids, there is an accumulation of
7␣-hydroxylated precursors to bile acids containing an intact side chain, in particular 7␣-hydroxy-4-cholesten-3-one
(Fig. 2). This accumulation is further increased as a consequence of the markedly reduced formation of the bile acid
chenodeoxycholic acid. The latter bile acid is the most ef-

Surprisingly, this locus was very recently identified as
the gene coding for the CYP7B1 (46). To date, more than
20 unrelated, HSP-affected families with 17 different mutations in the CYP7B1 gene have been described (42–46).
Most patients with the SPG5 are “pure” with progressive
lower limb spasticity as the only symptom, but a few of the
patients can be regarded as “complicated” and also present ataxia, mental retardation, and neurological symptoms. At this time, it is not known whether it will be possible
to relate the site of the mutation and the degree of inhibition of the CYP7B1 activity to the clinical picture.
CYP7B1 is a 506 amino acid enzyme that catalyses the
7␣-hydroxylation of several steroids and SCOx [for a recent review, see (47)]. The enzyme is located in the endoplasmic reticulum and is dependent upon NADPH and
cytochrome P-450 oxidoreductase for activity. The enzyme
has a broad tissue distribution and is present in liver, kidney, brain, and endocrine tissues. The substrate specificity
is broad and includes the two oxysterols 25-hydroxycholesterol (25-OHC) and 27-OHC (48). In addition, a number
of C19 and C21-steroids, e.g., dehydroepiandrosterone
and pregnenolone, are substrates for the enzyme (49).
CYP7B1 is evolutionarily conserved and is of importance
both for bile acid synthesis and for metabolism of neurosteroids. Its role in bile acid synthesis is well defined, because
the alternative pathway to bile acids starting with a 27hydroxylation of cholesterol as the first step in the liver
or in extrahepatic tissues is dependent on CYP7B1 (12).
The metabolism of 27-OHC in the brain also requires
CYP7B1 (27). The importance of CYP7B1 in connection
with the turnover of the neurosteroids dehydroepiandrosterone and pregnenolone is less well defined. As anticipated, SPG5 patients have increased plasma levels of 27OHC (6- to 9-fold) and 25-OHC (100-fold) (50). A 30- to 50fold increase in 27-OHC was found in cerebrospinal fluid.

A disruption of the gene coding for Cyp7b1 in mice
leads to accumulation of 27-OHC and 25-OHC in the circulation, but otherwise the mice have no obvious phenotype (51). This is in contrast to the situation in humans;
mice with a knockout of Cyp7b1 do not develop spastic
paresis in spite of the elevated levels of 25-OHC and 27OHC. A transgenic mouse model overexpressing human
CYP27A1 has also been developed and characterized (52).
As with the Cyp7b1 knockout mice, the CYP27A1 transgenic mice have increased levels of 27-OHC, levels similar
to those in Cyp7b1-deficient mice. As with the Cyp27a1
knockout mice, the CYP27A1 transgenic mice do not present any obvious phenotype.
It may be concluded from the experiments with Cyp7b1deficient and Cyp27a1-overxpressing mice that high levels
of 25-OHC and 27-OHC are not sufficient to cause obvious
neurological deficits. The situation is different in humans,
however. The absolute plasma levels of the two SCOx are
about 5-fold higher in patients with the SPG5 disease than
in the above mouse models. Another factor that may be of
importance is the relatively small corticospinal tract and its
redundancy in rodents compared with humans (49).
Thus, we do not know if it is the high levels of the oxysterols or the defective metabolism of neurosteroids that is
the most important pathogenetic factor in patients with the
SPG5 disease. SCOx such as 25-OHC and 27-OHC are known
to be cytotoxic to cultured cells (20, 53). It has been reported
that 25-OHC induces production of interleukin-1␤ and interleukin-8 from human macrophages (54, 55) as well as altering the production of IgA (56). We have discussed the
possibility that a local interleukin release as a consequence
of the high levels of 25-OHC may be a pathogenetic factor in
the SPG5 patients (50).
The brains of patients with AD have reduced levels of
CYP7B1 (57), probably as a consequence of the neuronal
Cholesterol and neurological disease
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Fig. 2. Metabolic relation between bile acid synthesis and formation of cholestanol in patients with CTX
(30, 36).

Huntington’s disease
Huntington’s disease (HD) is an inherited dominant
neurodegenerative disorder characterized by a glutamine
expansion within the N terminus of the huntingtin protein (HTT) (64). It has a prevalence of 3–10 affected subjects/100,000 individuals in Western Europe and North
America. The CAG trinucleotide repeats is located within
the coding region of exon 1 of the huntingtin gene, which
is located on the short arm of chromosome 4 (4p63).
HTT is a protein composed of more than 3,100 amino
acids with a molecular weight of about 349 kDa, depending on the exact number of glutamine residues. A polymorphic proline-rich segment follows the polyglutamine
tail. Within the cell, wild-type HTT is mainly localized in
the cytoplasm but is also associated with mitochondria,
Golgi apparatus, endoplasmic reticulum, synaptic vesicles,
and several components of the cytoskeleton. A small
amount of HTT can also be found in the nucleus. The
2494
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wild-type HTT is essential for normal embryonic development, because knockout mutations to exons 4 or 5 or to the
promoter results in embryonic lethality. HTT is widely expressed throughout the body, and it has been ascribed numerous roles in various intracellular functions, including
protein trafficking, vesicle transport and anchoring, clathrin-mediated endocytosis, postsynaptic signaling, and transcriptional regulation, as well as antiapoptotic function
(65). In the HD brain, particularly in striatum and cerebral cortex, an altered intracellular localization and perinuclear accumulation of mutant HTT is observed, with the
formation of neuronal intranuclear inclusions (66) and
aggregates in dystrophic neurites (67). Such aggregates
are considered the pathological hallmarks of HD and can
be present in gene-positive premanifest subjects who are
close to the estimated age-at-onset (68).
The expanded polyglutamine is thought to confer a new
function to HTT that is toxic to the cell and impairs the
correct function of the protein. The mutant protein tends
to auto-aggregate and to promote aberrant protein-protein interactions in several subcellular locations (69), leading to the disruption of several intracellular pathways. The
loss of function contributes to the disruption of intracellular homeostasis, leading to neuronal dysfunction and
death. The contribution of both toxic gain of function and
loss of function of wild-type HTT culminates in neuronal
dysfunction as an overall consequence of activation of protease, protein misfolding, transcriptional deregulation,
proteasome impairment, oxidative injury, mitochondrial
dysfunction, and disruption of axonal transport and synaptic function (64).
A classic degenerative feature of HD is the gradual atrophy of the striatum (caudate nucleus and putamen) together with astrogliosis (70). The most afflicted neuronal
populations are the medium-sized projection spiny neurons, which correspond to 95% of the striatal neuronal
population. Because these ␥-amino butyric acid-utilizing
neurons are inhibitory, it is thought that the loss of their
inhibition is the underlying cause of the uncontrolled
movement characteristic of HD (71). According to MRI
investigations, there is also a severe cortical atrophy combined with striatal degeneration. The loss in brain mass is
quite substantial in HD: during the 15–20 years of the disease course from the onset of symptoms to death, the brain
weight declines in patients from an average of 1.350 g to
<1.100 g (71). The clinical associates of such dramatic
neurodegeneration, mainly occurring in the striatum and
cortex (72), are progressive motor deterioration including
chorea and dystonia. In addition there, are psychiatric and
behavioral abnormalities, which may precede or accompany the motor onset and cognitive decline (73). Neuropathological findings in HD are mirrored by evidence of
progressive atrophy of the striatum on MRI scans (68).
The expression of some important genes involved in the
cholesterol biosynthetic pathway, HMGCR, sterol 14-␣
demethylase, and 7-dehydrocholesterol 7-reductase, is reduced in inducible mutant HTT cell lines as well as in striatum and cortex from transgenic R6/2 HTT-fragment mice
(74). These changes are also present in brain and fibroblasts
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location of this enzyme and the neuronal loss in this disease. In accordance with this, the brains of these patients
contain elevated levels of 27-OHC (58). The possibility has
been discussed that this accumulation may be of some
pathogenetic importance (28). If the accumulation of 25OHC and 27-OHC is the most important pathogenetic factor in the SPG5 disease, it may be beneficial to reduce the
levels of these oxysterols. Because it is known that substrate
availability is a limiting factor for CYP27A1 activity, we have
suggested that a possible therapeutic strategy could be to
treat the patients with a cholesterol synthesis inhibitor
(50). Such treatment is thus known to reduce the levels of
27-OHC in parallel with cholesterol.
HSP is, however, not the only pathological consequence
of a mutation in the CYP7B1 gene. A decade before the link
between SPG5 and CYP7B1 was reported, a fatal case with
mutations in the CYP7B1 gene was reported, an infant who
died in the neonatal stage with liver failure (59). Whether
or not the mutation was causative or a contributing factor
to the death of the infant is not known with certainty. The
10-week-old boy presented with severe cholestasis, cirrhosis, and liver failure. The plasma levels of 27-OHC were
increased more than 1,000 times those of normal controls,
considerably higher than in adult patients with SPG5. Another oxysterol, 24S-OHC, was increased by a similar magnitude in spite of the fact that this oxysterol is not a
substrate for CYP7B1 (60). The latter finding suggests that
other factors than the loss of the CYP7B1 activity must
have contributed. More recently, another neonatal case
was described with severe cholestatic liver disease, a mutation in the CYP7B1 gene and a fatal outcome (61). The
levels of oxysterols were never measured in this patient. To
our knowledge, neonatal cholestasis has not been reported
in any adult patient with the SPG5 disease. Thus, it seems
likely that other factors than a CYP7B1 mutation must
have contributed to the severe cholestasis in the two neonatal patients described thus far. The situation may be
similar to that in patients with CTX. A few neonatal cases
of this disease have been described with severe cholestasis
(62, 63).

Niemann-Pick disease
Niemann Pick disease Type C (NPC) is a rare autosomal
recessive neurovisceral lipid storage disease with no known
cure (80). Progressive neurological disease is a hallmark
and is responsible for disability and premature death beyond early childhood. The neurological symptoms include

ataxia, dysathria, dysphagia, tremor, and epilepsy. In the
terminal stages, the patients have a loss volitional movements and are severely demented. Mutations in the NPC
type C1 (NPC1) and NPC type C2 (NPC2) specific genes
have been identified as the cause of the disease, with mutations in NPC1 responsible for the vast majority (95%) of
clinical cases (81). Unusually, despite very similar clinical
manifestations, the NPC1 and NPC2 proteins are unrelated. NPC1 is a large membrane-anchored protein with
homology to HMGCR, SREBP cleavage activating protein,
and patched 1, a gene involved in Hedgehog signaling
(82, 83). In contrast, NPC2 is a small soluble glycoprotein
(81). The common clinical picture is thought to be a consequence of the fact that both NPC1 and NPC2 participate in the movement of lipids, in particular cholesterol,
out of the endolysosomal system. This has led to the consensus that NPC disease is a cholesterol storage disease.
NPC patients have a markedly impaired capacity for cholesterol esterification and accumulate free cholesterol,
which may be directly observed by staining cultured fibroblasts from the patients with fluorescent probes such as
filipin (84). The latter procedure is regarded to be the
best diagnostic test.
As mentioned above, almost all cases of NPC disease
arise from mutations in NPC1. NPC1 is a large (1,278
amino acid) transmembrane protein with 13 putative
membrane-spanning regions interspersed by various loops
projecting into the lumen of endosomes or lysosomes
(82). There is significant homology between helices 3-7
and the so-called sterol sensing domain of other proteins
involved in cholesterol turnover (SREBP cleavage activating protein and HMGCR) and hedgehog signaling
(patched 1), indicating that there may be a common
mechanism for sterol sensing. Using a photoactivable cholesterol analog, Ohgami et al. (85) showed that sterol
binding to NPC1 required a functional sterol sensing domain. More recent studies by Infante et al. (86) have confirmed and extended these observations. In an unbiased
screen to identify a membrane-bound oxysterol binding
protein, Infante et al. (86) reported, somewhat unexpectedly, that intact recombinant NPC1 was capable of binding
SCOx as well as cholesterol. The highest affinity binding
occurred with 24S-, 25-, and 27-OHC. Notably, the authors
reported that while SCOx were able to impair the binding
of cholesterol, the reverse was not true, implying that there
was more than one sterol binding site in the molecule and
indeed suggesting that separate cholesterol and oxysterol
binding sites are present (86). In a subsequent study, the
same group defined a well-conserved, 240 amino acid loop
region of NPC1 as the sterol binding site. Using a recombinant protein, these authors were able to demonstrate
that sterol binding was saturable in this region, with a 13fold higher affinity for 25-OHC compared with cholesterol
(Kd 10 nM vs. 130 nM, respectively), indicating that this is
the oxysterol binding site on the protein (87). Because the
brain contains about 0.1 mM levels of 24S-OH, it can be
speculated that this site is largely saturated with this oxysterol
under in vivo conditions. The potential functional role of
such binding is impossible to evaluate with the present
Cholesterol and neurological disease
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from HD patients (75). Additional studies showed that
cholesterol synthesis and accumulation (as indicated by
content of the cholesterol precursors lanosterol and
lathosterol and by decreased enzymatic activity of HMGCR)
are significantly reduced in the brain of several rodent
models such as the R6/2 mice, the yeast artificial chromosome mice, the (HdhQ111/111) Hdh knockin mice, and others (76, 77) (Valenza and Leoni, unpublished observations).
The degree of reduction of cholesterol synthesis and accumulation was found to increase with the length of the
CAG repeats, the amount of mutated HTT, and age. Thus,
the levels of cholesterol and precursors are only slightly
reduced in young animals and much more reduced in
older animals (Valenza and Leoni, unpublished observations). The molecular mechanism underlying this dysfunction appears to be a mutant HTT-dependent decrease in
the amount of active gene coding for sterol regulatory element binding protein (SREBP), resulting in less activation
of SREBP-controlled genes. The molecular mechanism behind the mutation in the huntingtin gene and the reduced
level of SREBP is not known with certainty, however.
Interestingly, wild-type HTT is able to bind to nuclear
receptors involved in lipid metabolism like LXR, PPAR␥,
and vitamin D receptor (78). Overexpression of HTT thus
activates LXR, whereas in cells with a lack of HTT, there is
an inhibition of LXR-mediated transcription. The possibility must be considered that in the case of HD, the mutated
HTT is less able to upregulate LXR and LXR-targeted
genes, including SREBP. Such a mechanism is a possible
link between the HTT mutation and the disturbances in
cholesterol metabolism. Further work is needed, however,
to establish this.
Neurodegeneration, with loss of neurons, would be expected to lead to reduced levels of CYP46A1 with subsequent reduction in the formation of 24S-OHC and a lower
efflux from the brain to the circulation. In accordance
with this, the 24S-OHC content was reduced in both brain
and circulation of yeast artificial chromosome 128 mice
(76). In a large cohort of controls, HD patients and genepositive premanifesting patients, a significant reduction of
plasma levels in 24-OHC was observed in clinically manifesting patients. Notably, this reduction was correlated to
the shrinking of striatum as estimated by MRI. In the case
of preHD, it was found that patients closer to the onset of
symptoms had levels similar to the HD stage 1 patients,
and those far from onset had levels similar to those of controls (79). It is likely that the observed reduction of cholesterol turnover is a consequence of a loss of metabolically
active neurons in brain. In a population of gene-positive,
pre-HD individuals, we observed a reverse relationship between length of the CAG repeats and plasma levels of 24SOHC (Leoni, unpublished observations).
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NPC phenotype in cultured cells, Lloyd-Evans et al. (97)
were able to show a very rapid (within 10 min) accumulation of sphingosine followed by the accumulation of cholesterol and other lipids. It should be noted, however, that
U18666A may interact with many other proteins, complicating the interpretation of this model. This compound is
an inhibitor of oxidosqualene cyclase, a key enzyme in the
synthesis of cholesterol (98). The authors speculated that
the accumulation of sphingosine disturbs lysosomal calcium homeostasis and leads to impaired vesicle trafficking
and fusion (97). Indeed, these authors report the accumulation of sphingosine (3-fold) and sphingosine-1-phosphate (7-fold) in the brain of NPC1 null mice. Moreover,
by treating the mouse model with a large dose of curcumin
(150 mg/kg/day), a compound able to elevate cytosolic
calcium levels, the authors were able to increase the life
expectancy of the mice. It should be noted that S1P has
recently been recognized as an endogenous histone
deacetylase inhibitor and that by inhibiting CBP/p300 histone acetyl transferase activity, curcumin is able to modulate gene expression (99). Given that there is accumulating
evidence that sterol homeostasis is under epigenetic control, the proposed mechanistic explanation for the action
of curcumin may not be the entire story (14, 15, 100).
A recent report indicates that the sphingosine analog
FTY720 can stimulate formation of 27-OHC and activate
LXR (101). This implies that enhanced formation of SCOx
may be a general mechanism engaged to reduce cholesterol in the endolysosomal system. The recent recognition
that the STARt domain containing protein MLN64 is able
to promote movement of cholesterol to the mitochondria
(the site of 27-OHC formation) in the absence of functional NPC1 adds weight to the concept that formation of
27-OHC is a compensatory mechanism (102). Very recent
data on the levels of 27-OHC in the plasma of NPC1 null
mice has provided some support for this; these levels are
markedly elevated (103). However, given the role of
CYP7B1 in the metabolism of 27-OHC, it cannot be excluded that metabolism is impaired rather than synthesis
increased. In contrast, cultured fibroblasts from NPC patients have a decreased level of 27-OHC (104, 105).
The very recent report on the effectiveness of cyclodextrin therapy further supports the role of cholesterol rather
than sphingosine as the pathogenic factor. Treatment of
NPC1 knockout mice with cyclodextrin effectively overcame the transport defect in NPC disease and led to excretion of cholesterol (as bile acids) from the affected mice,
with the exception of the lungs (106). Early treatment (7
days postnatally) resulted in a significant increase in the
lifespan of the affected animals (107). A human trial of
this therapy is currently underway.
Very recent data has been presented indicating that the
plasma concentration of certain oxysterols, in particular
the auto-oxidation products 7-oxocholesterol and cholestane 3,5,6-triol, is elevated in NPC disease, indicating a possible role for measurement of these sterols in the diagnosis
and/or monitoring of NPC disease (103, 108). These data
are consistent with the previous demonstration by Alvelius
et al. (109) that the urine of an NPC patient contains unusual
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knowledge, although it is possible that it may influence
cholesterol supply to the ER, where 24S-OHC is synthesized. Emerging studies have indicated that the expression
of NPC1mRNA and protein are regulated by LXR both in
vitro and in vivo. Oxysterols such as 24S-OHC (86–88) are
thought to be responsible for the activation in vivo. In this
connection, it is of interest that treatment with LXR agonists increased the lifespan of NPC null mice (89). In the
brain in particular, the convergence of different pathways
on the 24S-OHC underscores the importance of this metabolite for brain cholesterol homeostasis.
In contrast to NPC1, NPC2 is a small (132 amino acid)
soluble glycoprotein present in both the lysosomes and in
various secreted fluids [to date, NPC2 has been identified
in milk, epididymal fluid, plasma, and bile (88–90)]. The
structure of NPC2 has been determined, and functional
studies have confirmed that the loosely packed hydrophobic core is an authentic cholesterol binding pocket and
that NPC2 binds cholesterol with low micromolar binding
affinities (91). Available data indicate that cholesterol is
oriented such that the 3␤-hydroxy group is at the entrance
to the binding site, and the remainder of the hydrophobic
cholesterol molecule is buried within the NPC2. Notably,
it has also been shown using competition assays that SCOx
are unable to bind to NPC2 (92). Despite the clear data on
cholesterol binding to NPC2, studies have shown that although some point mutations do not significantly affect
the capacity for cholesterol binding, they do impair the
ability of exogenous NPC2 to correct NPC2 deficiency in
cell systems. It has been proposed that NPC2 facilitates the
rapid movement of cholesterol between lipid bilayers to
NPC1, providing a plausible explanation for how mutations in either of these unrelated proteins may lead to
clinical manifestations of the disease (93).
Accumulation of free cholesterol in tissues is a consistent finding in NPC patients, including the brain (94),
where cholesterol may also be redistributed within individual neurons (95). It should be noted that the extremely
long half-life of the majority of brain cholesterol has obscured the direct identification of cholesterol accumulation using analytical biochemical methods. However, using
filipin microfluorodensitometry, Treiber-Held et al. (94)
demonstrated a significant accumulation of cholesterol in
the brains of NPC1 null mice, with the cholesterol accumulating before the onset of a disease phenotype. A consequence of cholesterol accumulation of this is that the
neurons become distorted; NPC patients often have ectopic dendrite formation and neurofibrillary tangles similar
to those see in AD (96). The Purkinje cells of the cerebellum seem particularly vulnerable to the effects of cholesterol accumulation, perhaps related to the capacity of the
cerebellum to synthesize cholesterol.
In addition to cholesterol, several other lipids have been
found to accumulate in NPC disease, most notably sphingomyelin in the periphery and glycosphingolipids in the
brain (for details, see the review from Xu et al. in this Thematic Series). Very recently, it was proposed that the earliest defect in NPC disease is accumulation of sphingosine
(97). Using the class II amphiphile U18666A to induce

7-oxygenated bile acid sulfates, possibly representing the
elimination product of 7-oxocholesterol. It is difficult to
understand the origin of these sterols, which are likely to
be formed by autooxidation rather than by enzymes. It has
been reported that ferritin is deficient in NPC disease, suggesting a block in iron homeostasis and an inability to correctly store iron, which is consistent with the known pathway
for the internalization of transferrin (110, 111). Because
iron is known to be able to catalyze the formation of oxysterols from cholesterol via the Fenton reaction, it is feasible that the accumulation of cholesterol leads to the
expansion of a pool of substrate for this reaction in vivo in
conjunction with iron accumulation. Chodhury et al. (112)
have demonstrated that increased membrane cholesterol
disturbs the endolysosomal pathway in a general sense,
which would be anticipated to impair the transfer of iron
from transferring to ferritin. Moreover, transcriptomic
studies have indicated that there is a modest increase in the
expression of genes involved in oxidative stress in NPC
cells, proving some support for this idea (113).

AD is a devastating neurodegenerative disorder. In the
Western population, it has been estimated that about 10%
of the population over the age of 65 years and one-half
those over age 85 years have AD (114, 115). The most
important characteristic of AD pathology is the presence
of extracellular ␤-amyloid containing senile plaques and
-protein containing neurofibrillary tangles in the neuronal
cells. In rare cases of familiar forms of AD, three distinct
genes have been identified that are of importance for generation of amyloid: the APP gene and the presenilin 1 and
presenilin 2 genes. Mutations in these genes result in overproduction of amyloid ␤ (A␤)-peptides or the proportion
of the longer A␤42 form. The longer form is regarded to
be more amyloidogenic and toxic than the shorter form
due to its highly aggregative nature (116). The clinical
consequences of the mutations in the above genes have
led to the “amyloid hypothesis” according to which increased synthesis or decreased degradation of A␤ is the
most important factor behind the neuroinflammation,
neurodegeneration, memory loss, and senile dementia in
AD (116). In addition to the amyloid-containing plaques,
oligomers of A␤ in the cytoplasm of neurons are thought
to be important for the pathogenesis.
Except for the rare cases with a defined mutation in one
of the above critical genes (<2% of the patients), AD is a
multifactoral disease. It is possible that the amyloid cascade
is not always the driving force and there is an imperfect
histopathological correlation of plaque deposition on one
hand and neuronal loss and dementia on the other hand.
At present, the possibility cannot be excluded that AD often is a consequence of a disruption of more fundamental
cellular functions that, when impaired, kill neuronal cells
and promote plaque formation in the process (117).
Hypercholesterolemia in mid-life is one of several factors associated with a moderately increased risk to develop

Hypercholesterolemia as a risk factor for AD
Hypercholesterolemia is a risk factor not only for atherosclerosis but also for AD. Increased cholesterol levels in
midlife have been linked to AD-type pathology in autopsy
studies (130, 131). Treatment of rabbits and mice with
cholesterol-enriched diets has been reported to result in
cerebral accumulation of amyloid (132, 133). The highly
unphysiological conditions used for the animal experiments makes it difficult, however, to draw firm conclusions. In a recent study, it was found that the induction of
AD-like neuropathology by dietary cholesterol depends on
the quality of the water that the animal was drinking
(134).
In view of the fact that lipoprotein-bound cholesterol in
the circulation does not pass the blood-brain barrier under normal conditions, it is difficult to understand the
mechanism by which hypercholesterolemia increases the risk
for neurodegeneration. We have suggested that the oxysterol 27-OHC could be a link between hypercholesterolemia and neurodegeneration (28, 29). In contrast to
Cholesterol and neurological disease
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AD (118, 119). The most important cholesterol-associated
risk factor is, however, presence of the 4 isoform of the
cholesterol transporter APOE [for reviews, see (120, 121)].
In addition, recent genome wide association studies have
provided compelling evidence that genetic variations in
APOJ are associated with the risk of developing AD (122–
124). However, the precise mechanistic connection(s) between these genes and AD remain poorly described. This
is made all the more difficult by the fact that current data
indicates a role for APOE in both brain sterol balance and
clearance of ␤-amyloid (125). Regardless of the specific
role of APOE (and possibly APOJ) in ␤-amyloid metabolism, it is evident that there must be significant overlap
with pathways governing cholesterol balance, and expression of APOE is known to be regulated by cholesterol.
The concentration of cholesterol in the critical membranes is of importance for the balance between ␣- and
␤-secretase activity, with consequences for the rate of generation of amyloid (126). Both APP and A␤ are at least in
part associated with cholesterol-rich domains and increased concentrations of cholesterol leads to increased
production of A␤. Conversely, however, ␤-amyloid may
affect cholesterol synthesis or efflux and the concentration of cholesterol in the membranes (127, 128). Thus,
it is possible that there is a negative feedback cycle in
which increased cholesterol increases production of A␤
that in turn inhibits cholesterol synthesis. Under some
conditions, this balance may, however, be disrupted with a
switching toward the amyloidogenic pathway. Also, the
state of  phosphorylation is affected by cholesterol levels
in the lipid rafts, with reduced cholesterol stimulating
phosphorylation (129).
A detailed description of the great number of different
factors involved in neurodegeneration possible to modulate by cholesterol is, however, beyond the scope of this
article. Here, we focus on two established genetic risk factors for AD: hypercholesterolemia and presence of the 4
isoform of APOE.

Role of APOE and its different isoforms in AD and other
neurodegenerative diseases
The strongest risk factor known for nonfamiliar AD is
the genotype for the cholesterol transporter APOE [for
general and more detailed reviews, see (120, 121)]. The
fact that the ApoE genotype might account for at least
50% of AD in a Caucasian population is one of the most
obvious indications of the importance of cholesterol
homeostasis for development of a neurodegenerative disease. It should be emphasized, however, that given the
pleiotrophic physiological functions of APOE, part of the
genetic association with neuropathological disease may be
unrelated to the known role of the protein in cholesterol
metabolism.
APOE, a 34 kDa protein composed of 299 amino acids,
is the most important lipoprotein for uptake of lipoproteins by the LDL receptor, the LDL receptor related protein, the APOE receptor 2, the VLDL receptor, and
megalin (119, 120). In humans, the APOE gene shows
polymorphism with three different alleles (E2, E3, and
E4) that gives rise to six different phenotypes (E2/2, E2/3,
E2/4, E3/3, E3/4, E4/4). APOE3 is the most common isoform (77–78%), while APOE2 is found in 7–8% and APOE4
in 14–16% in most Western populations. Subjects with one
or two copies of APOE4 have a higher risk of developing
AD compared with carriers of other isoforms. APOE also
reduces the median age for AD onset from 84 in noncarriers to 68 in E4 homozygotes. The E4 allele occurs in about
60% of AD patients (about 15% with E4/4, 40% with E3/4,
and <5% with APOE2/4). The 2% of the population with
2498

Journal of Lipid Research Volume 51, 2010

the E4/4 genotype carries about 15 times the risk of the
60% of the population that has the E3/3 genotype. It has
been reported that no APOE4/4 carrier has been shown
to reach the age 90 without having AD (139).
From a structural point of view, the difference among
the three isoforms is minor, involving only two amino
acid positions [E2 (cys112,cys158), E3 (cys112,arg158), and E4
112
158
(arg ,arg )].
These changes affect the three-dimensional structure as
well as the lipid binding properties of the isoforms. Thus,
APOE3 and APOE2 preferentially bind HDL, whereas
APOE4 preferentially binds VLDL. It is likely that this
change will affect the capacity of APOE to participate in
the distribution of lipids necessary for proliferation, synaptogenesis, and myelinization of axons. It important to note
that humans are the only species that has arg61 in APOE,
which leads to domain interaction as a second layer of
structural complexity.
The evolutionary history of APOE genotypes in humans
is unique and has been proposed to be a result of adaptive
changes (120, 121). According to current concepts, the
APOE4 allele is the ancestral gene, existing alone until
300,000 years ago, at which time the APOE3 allele appeared. The APOE2 allele mutated from the E3 allele
about 200,000 years ago. Introduction of the new APOE
genotypes provided better cognitive and cardiovascular
function to those rare subjects who survived beyond 60
years of age at that time. The retention of more elderly
subjects with intact cognitive function in the population
may have been important for accumulation of knowledge
and expansion of human populations (139).
A great number of studies have appeared demonstrating that the association of APOE4 to AD affects the majority of the pathological events in AD (A␤-generation and
deposition, formation of neurofibrillary tangles, neuronal
survival, lipid homeostasis, intracellular signaling) (121).
With respect to A␤-generation, APOE4 has been shown to
stimulate endocytic recycling of APP, resulting in increased
net production (140). In contrast to APOE4, APOE3, and
APOE2 seem to have a protective role by inhibiting A␤ aggregation and/or favoring A␤-clearance (141).
Under in vitro conditions, APOE3 but not APOE4 forms
a stable complex with . Phosphorylation of  inhibits its
interaction with APOE3, suggesting that APOE3 only binds
to nonphosphorylated . Based on this, it has been suggested that APOE3 might be able to prevent the abnormal
hyperphosphorylation occurring in AD and the destabilization of the neuronal cytoskeleton (142). The carboxy
terminal-truncated form of APOE4 is neurotoxic and stimulates  phosphorylation (143). The enzymatic cleavage of
APOE to give the carboxy-terminal truncated form may
thus be important, and it has been shown that the serin
protease involved in this hydrolysis cleaves APOE4 more
efficiently than APOE3. The APOE fragments are generated
inside cultured neuronal cells and in AD brains and may
interact with phospho- and phosphorylated neurofilaments
of high molecular weight, resulting in large filamentous
intracellular inclusions in the neuronal cells (144). Studies with transgenic mice have shown increased phosphory-
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cholesterol, 27-OHC passes the blood-brain barrier and
there is a positive correlation between levels of cholesterol
and 27-OHC in the circulation (135). Thus, it is likely that
hypercholesterolemia leads to a higher uptake of 27-OHC.
The latter steroid has been shown to antagonize the preventive effect of 24S-OHC on generation of amyloid under
in vitro conditions (22, 23). In addition, 27-OHC has a
downregulating effect on the “memory protein” activityregulated cytoskeleton-associated protein in mouse brain
(136). The same effect is obtained by treatment of the
mice with a cholesterol-enriched diet, consistent with the
possibility that 27-OHC is the link between the hypercholesterolemia and the effect. Further studies are needed,
however, to clarify this.
If high cholesterol in the circulation is a pathogenetic
factor in AD, a lowering of these levels may be beneficial.
In view of the fact that hypercholesterolemia increases the
risk for AD by a factor of about 2 (119, 121), only relatively
small effects can be expected after treatment with lipidlowering drugs. A great number of clinical studies of different design have been performed with statins [for a
review see (137)]. Several of these studies have shown a
positive effect ,whereas others have been negative. Two
large, very well-designed, double-blind, randomized, placebo-controlled trials of statins in people at risk for dementia were, however, negative (138) and at present it is
not possible to conclude that statins have a protective effect on AD.
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